Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a poor
prognosis. Initial responses to standard-of-care chemo-immunotherapy are, unfortunately …

Chemotherapy has long been a standard treatment for a wide range of malignancies, where
patients typically undergo multiple rounds of chemotherapy regimens to control tumor …

Non–small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths. Immune
checkpoint blockade has improved survival for many patients with NSCLC, but most fail to …

Secondary immunodeficiency is reported in most patients with hematological malignancies
such as chronic lymphocytic leukemia and multiple myeloma. The aim of our review was to …

Methods: We examined whether immune cell profiles differ between healthy women (n= 38)
and breast cancer survivors (n= 27) within 2 years of treatment, and whether any group …

Glioblastoma is an aggressive primary brain tumor that has seen few advances in treatments
for over 20 years. In response to this desperate clinical need, multiple immunotherapy …

As one of the main threats to human life (the fourth most dangerous and prevalent cancer),
colorectal cancer affects many people yearly, decreases patients' quality of life, and causes …

Although immunotherapy can offer profound clinical benefit for patients with a variety of
difficult-to-treat cancers, many tumors either do not respond to upfront treatment with …

Adoptive immunotherapy, notably involving chimeric antigen receptor (CAR)-T cells, has
obtained Food and Drug Administration (FDA) approval as a treatment for various …

New evidence suggests that the clinical success of chemotherapy is not merely due to tumor
cell toxicity but also arises from the restoration of immunosurveillance, which has been …